Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTO Aptose Biosciences	$1.23	$1.60	$1.20 ▼ $8.70	$19.34M	1.29	88,255 shs	11,944 shs
BCLI Brainstorm Cell Therapeutics	$0.54 +1.9%	$0.47	$0.13 ▼ $3.37	$36.91M	0.27	1.01 million shs	365,604 shs
PDLI PDL BioPharma	$2.47	$2.47	$2.09 ▼ $3.86	N/A	N/A	N/A	N/A
RUBY Rubius Therapeutics	$0.06	$0.04	$0.00 ▼ $0.38	$5.16M	2.59	1.15 million shs	755,858 shs
TCRR TCR2 Therapeutics	$1.48 -5.7%	$1.65	$0.82 ▼ $3.88	$58.11M	1.95	494,777 shs	3.91 million shs

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTO Aptose Biosciences	-0.08%	-5.38%	-20.65%	-34.75%	-83.09%
BCLI Brainstorm Cell Therapeutics	+1.52%	-1.57%	-5.25%	+68.26%	-82.29%
PDLI PDL BioPharma	0.00%	0.00%	0.00%	0.00%	0.00%
RUBY Rubius Therapeutics	0.00%	0.00%	0.00%	0.00%	+143.59%
TCRR TCR2 Therapeutics	0.00%	0.00%	0.00%	0.00%	-14.45%

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (Ad)

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APTO Aptose Biosciences	1.1235 of 5 stars	3.5	3.0	0.0	0.0	0.6	0.0	0.6
BCLI Brainstorm Cell Therapeutics	1.0794 of 5 stars	0.0	3.0	0.0	4.7	3.1	0.0	0.6
PDLI PDL BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RUBY Rubius Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APTO Aptose Biosciences	3.00	Buy	$19.80	1,509.76% Upside
BCLI Brainstorm Cell Therapeutics	2.00	Hold	N/A	N/A
PDLI PDL BioPharma	N/A	N/A	N/A	N/A
RUBY Rubius Therapeutics	N/A	N/A	N/A	N/A
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest TCRR, PDLI, APTO, BCLI, and RUBY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/3/2024	APTO Aptose Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$5.00
3/27/2024	APTO Aptose Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
2/1/2024	APTO Aptose Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.00 ➝ $5.00

(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	($0.08) per share	N/A
PDLI PDL BioPharma	N/A	N/A	N/A	N/A	N/A	N/A
RUBY Rubius Therapeutics	N/A	N/A	N/A	N/A	$0.17 per share	N/A
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	$2.58 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APTO Aptose Biosciences	-$51.21M	-$7.72	N/A	N/A	N/A	N/A	-458.70%	-205.30%	5/13/2024 (Estimated)
BCLI Brainstorm Cell Therapeutics	-$17.19M	-$0.41	N/A	N/A	N/A	N/A	N/A	-376.40%	5/20/2024 (Estimated)
PDLI PDL BioPharma	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RUBY Rubius Therapeutics	-$179.67M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TCRR TCR2 Therapeutics	-$151.82M	-$4.20	N/A	N/A	N/A	N/A	-97.81%	-69.35%	N/A

Latest TCRR, PDLI, APTO, BCLI, and RUBY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/26/2024	Q4 2023	APTO Aptose Biosciences	-$1.48	-$1.44	+$0.04	-$1.44	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
PDLI PDL BioPharma	N/A	N/A	N/A	N/A	N/A
RUBY Rubius Therapeutics	N/A	N/A	N/A	N/A	N/A
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APTO Aptose Biosciences	N/A	0.78	0.78
BCLI Brainstorm Cell Therapeutics	N/A	0.24	0.24
PDLI PDL BioPharma	N/A	N/A	N/A
RUBY Rubius Therapeutics	N/A	N/A	N/A
TCRR TCR2 Therapeutics	N/A	2.96	2.96

Ownership

Institutional Ownership

Company	Institutional Ownership
APTO Aptose Biosciences	26.62%
BCLI Brainstorm Cell Therapeutics	14.33%
PDLI PDL BioPharma	N/A
RUBY Rubius Therapeutics	N/A
TCRR TCR2 Therapeutics	64.76%

Insider Ownership

Company	Insider Ownership
APTO Aptose Biosciences	9.53%
BCLI Brainstorm Cell Therapeutics	5.45%
PDLI PDL BioPharma	11.70%
RUBY Rubius Therapeutics	5.30%
TCRR TCR2 Therapeutics	25.01%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
APTO Aptose Biosciences	31	15.72 million	14.22 million	No Data
BCLI Brainstorm Cell Therapeutics	29	68.34 million	64.62 million	Optionable
PDLI PDL BioPharma	109	N/A	N/A	Optionable
RUBY Rubius Therapeutics	6	90.48 million	85.69 million	Not Optionable
TCRR TCR2 Therapeutics	137	39.26 million	29.44 million	Not Optionable

TCRR, PDLI, APTO, BCLI, and RUBY Headlines

Source	Headline
	TCR2 Therapeutics gets grant for recombinant nucleic acid encoding TCR fusion protein for cancer treatment pharmaceutical-technology.com - April 17 at 9:14 AM
	Poseida Therapeutics Inc Ordinary Shares PSTX morningstar.com - February 25 at 9:43 AM
	DICE Therapeutics Inc. wsj.com - June 20 at 11:13 PM
	Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company finance.yahoo.com - June 1 at 4:46 PM
	TCR2 Therapeutics Insider Trades Send a Signal benzinga.com - May 16 at 1:36 PM
	Recap: TCR2 Therapeutics Q1 Earnings msn.com - May 12 at 9:26 AM
	10-Q: TCR2 THERAPEUTICS INC. marketwatch.com - May 11 at 11:15 PM
	TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update finance.yahoo.com - May 11 at 8:13 AM
	Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite Risky finance.yahoo.com - April 15 at 12:05 PM
	Mizuho Downgrades Tcr2 Therapeutics (TCRR) msn.com - March 25 at 7:55 PM
	TCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho Securities markets.businessinsider.com - March 23 at 7:23 PM
	Analysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY) markets.businessinsider.com - March 23 at 2:23 PM
	TCR2 Therapeutics: TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update finanznachrichten.de - March 23 at 9:22 AM
	TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update finance.yahoo.com - March 23 at 9:22 AM
	What To Know About Jefferies's Downgrade of TCR2 Therapeutics msn.com - March 9 at 5:14 PM
	4 Analysts Have This to Say About TCR2 Therapeutics markets.businessinsider.com - March 9 at 12:14 PM
	TCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at H.C. Wainwright markets.businessinsider.com - March 8 at 8:52 PM
	Shareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with Adaptimmune benzinga.com - March 6 at 7:17 PM
	SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TCR² Therapeutics Inc. Buyout benzinga.com - March 6 at 7:17 PM
	Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today? investorplace.com - March 6 at 12:02 PM
	TCR2 Therapeutics: Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors finanznachrichten.de - March 6 at 8:28 AM
	Adaptimmune To Combine With TCR² In All-stock Deal - Quick Facts markets.businessinsider.com - March 6 at 8:28 AM
	Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors finance.yahoo.com - March 6 at 8:28 AM
	Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors finance.yahoo.com - March 6 at 8:28 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aptose Biosciences

NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Brainstorm Cell Therapeutics

NASDAQ:BCLI

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

PDL BioPharma

NASDAQ:PDLI

PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Rubius Therapeutics

NASDAQ:RUBY

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.

TCR2 Therapeutics

NASDAQ:TCRR

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial